Efficacy of Anti-CFA/I and CfaE Bovine Milk Immunoglobulin Against Challenge With H10407 ETEC Expressing CFA/I (BIgGI)

This study has been completed.
Sponsor:
Collaborators:
Naval Medical Research Center
Walter Reed Army Institute of Research (WRAIR)
Information provided by:
Johns Hopkins Bloomberg School of Public Health
ClinicalTrials.gov Identifier:
NCT00435526
First received: February 13, 2007
Last updated: February 14, 2007
Last verified: February 2007
  Purpose

The purpose of this study is to assess anti-CFA/I and anti-CfaE BIgG safety and to determine protective efficacy of anti-CFA/I and anti-CfaE BIgG against diarrhea after challenge with H10407, a CFA/I-expressing ETEC strain.


Condition Intervention Phase
Diarrhea
Biological: anti-CFA/I bovine IgG, and anti-CfaE bovine IgG
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: Protective Efficacy of Orally Delivered Bovine Milk Immunoglobulin (BIgG) Specific for the Minor CFA/I Fimbrial Adhesin CfaE Against Challenge With H10407 Enterotoxigenic E. Coli (ETEC) Strain Expressing CFA/I

Resource links provided by NLM:


Further study details as provided by Johns Hopkins Bloomberg School of Public Health:

Primary Outcome Measures:
  • Clinical diagnosis of diarrhea defined as 1 loose/liquid stool (≥ Grade 3) of >300 g OR ≥ 2 loose/liquid stools totaling ≥ 200 g during any 48-hour period within 120 hours of challenge with ETEC strain H10407.

Secondary Outcome Measures:
  • Prevention of moderate to severe diarrhea.

Estimated Enrollment: 30
Study Start Date: March 2006
Estimated Study Completion Date: October 2006
Detailed Description:

This is a Randomized, double-blinded, placebo-controlled trial involving up to 33 subjects. Subjects will be randomized into one of the following three groups.

Group N Product

  1. 10 BIgG anti-CFA/I
  2. 10 BIgG anti-CfaE
  3. 10 LactoFree® Lipil®

Volunteers will receive the test article three times daily following meals beginning 2 days prior to oral ETEC challenge (strain H10407). Test article will be administered for a total of 7 days. Monitoring procedures will assess volunteer safety, the primary endpoint (diarrhea), stool microbiology (H10407 excretion), and ETEC-specific immunology. All volunteers will receive antibiotic treatment (ciprofloxacin, trimethoprim-sulfamethoxazole or amoxicillin) starting 5 days after ETEC challenge or sooner based on pre-defined clinical criteria. Follow-up visits for 2 weeks post-discharge will monitor safety and immunological parameters.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female between 18 and 45 years of age.
  • General good health, without significant medical illness, abnormal physical examination findings or clinical laboratory abnormalities as determined by principal investigator.
  • Demonstrate comprehension of the protocol procedures and knowledge of ETEC illness by passing a written examination (pass grade ≥ 70%)
  • Willing to participate after informed consent obtained.
  • Available for all planned follow-up visits.
  • Negative serum pregnancy test at screening and a negative urine pregnancy test on the day of admittance to the inpatient phase for female volunteers of childbearing potential. Females of childbearing potential must agree to use an efficacious hormonal or barrier method of birth control during the study. Abstinence is acceptable. Female volunteers unable to bear children must have this documented (e.g., tubal ligation or hysterectomy).

Exclusion Criteria:

  • Presence of a significant medical condition, (e.g. psychiatric conditions or gastrointestinal disease, such as peptic ulcer, symptoms or evidence of active gastritis or gastroesophageal reflux disease, inflammatory bowel disease, alcohol or illicit drug abuse/dependency), or other laboratory abnormalities which in the opinion of the investigator precludes participation in the study.
  • Immunosuppressive illness or IgA deficiency (below the normal limits)
  • Positive serology results for HIV, HBsAg, or HCV antibodies.
  • Significant abnormalities in screening lab hematology, serum chemistry, urinalysis or EKG (EKG in volunteers ≥ 40 years), as determined by PI.
  • Allergy to fluoroquinolones, trimethoprim-sulfamethoxazole, or ampicillin/penicillin (excluded if allergic to two of three).
  • Abnormal stool pattern (fewer than 3 stools per week or more than 3 stools per day) on a regular basis.
  • History of diarrhea in the 2 weeks prior to planned inpatient phase
  • Regular use of laxatives, antacids, or other agents to lower stomach acidity (regular defined as at least weekly).
  • Use of antibiotics during the 7 days before dosing or proton pump inhibitors, H2 blockers, or antacids within 48 hours of dosing.
  • Travel to countries where ETEC or cholera infection is endemic (most of the developing world) within two years prior to dosing.
  • History of vaccination for or ingestion of ETEC, cholera, or LT toxin.
  • Stool culture (collected no more than 1 week prior to admission) positive for CFA/I + ETEC or other bacterial enteric pathogens (Salmonella, Shigella and Campylobacter).
  • Use of any investigational drug or any investigational vaccine within 30 days preceding the first dose of test article, or planned use during the active study period.
  • Clinical history of lactose intolerance or allergy to milk or milk products.
  • Use of any medication known to affect the immune function (e.g., corticosteroids and others) within 30 days preceding the first dose of study vaccine, or planned use during the active study period.
  • Inability to tolerate an over-the-counter, lactose-free, infant, powder formula suspended in 150 mL sodium bicarbonate buffer (based on requirement for frequent dosing).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00435526

Locations
United States, Maryland
Johns Hopkins Bayview Medicial Center, Inpatient Unit
Baltimore, Maryland, United States, 21224
General Clinical Research Center
Baltimore, Maryland, United States, 21287
Sponsors and Collaborators
Johns Hopkins Bloomberg School of Public Health
Naval Medical Research Center
Walter Reed Army Institute of Research (WRAIR)
Investigators
Principal Investigator: Robin McKenzie, M.D. Johns Hopkins School of Public
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00435526     History of Changes
Other Study ID Numbers: CIR 218, HMJF Sub Award # 0000090523
Study First Received: February 13, 2007
Last Updated: February 14, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Johns Hopkins Bloomberg School of Public Health:
traveler's diarrhea
ETEC diarrhea
passive immunization
bovine milk prophylaxis

Additional relevant MeSH terms:
Diarrhea
Signs and Symptoms, Digestive
Signs and Symptoms
Immunoglobulins
Antibodies
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 25, 2014